Treatment
Onvansertib clinical trials
We’re tracking 4 recruiting studies that include Onvansertib, each written for real people, not researchers, below.
Recruiting studies
- NCT05450965RecruitingPhase 2
Onvansertib for relapsed small cell lung cancer
This trial studies onvansertib, a targeted medicine, in people whose small cell lung cancer has come back or did not respond to prior platinum chemotherapy. It aims to shrink tumors and improve outcomes after standard treatment has already been tried.
Baltimore, MarylandAges 18 years+ - NCT05549661RecruitingPhase 1
Onvansertib for hard-to-treat CMML and MDS/MPN
This Phase 1 study tests onvansertib to see if it can help people with repeat or treatment-resistant chronic myelomonocytic leukemia (CMML) and MDS/MPN overlap. It also studies side effects and gathers blood/bone marrow samples to better understand how the treatment works.
Rochester, MinnesotaAges 18 years+ - NCT06736717RecruitingPhase 1/Phase 2
Testing onvansertib plus chemo for first-line advanced pancreatic cancer
This trial tests a new drug called onvansertib combined with standard chemotherapy (NALIRIFOX) as the first treatment for advanced pancreatic cancer that cannot be removed by surgery or has spread. The goal is to see if adding onvansertib helps shrink tumors or slow the cancer better than chemo alone.
Kansas City, KansasAges 18 years+ - NCT04005690RecruitingEarly Phase 1
Targeted drug treatment for pancreatic cancer using pathway changes
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
Portland, OregonAges 18 years+
What Onvansertib is being studied for
Conditions with recruiting Onvansertib studies.
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Stage II Pancreatic Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Unresectable Pancreatic Ductal Adenocarcinoma
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Resectable Pancreatic Ductal Adenocarcinoma
- Small Cell Lung Cancer
- Small Cell Lung Carcinoma
Common questions
- Are there clinical trials studying Onvansertib?
- Yes. Clin2 currently lists 4 recruiting studies that include Onvansertib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Onvansertib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Onvansertib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Onvansertib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.